H1.2 deletion suppresses cancer progression and reduces GSH levels in small GTPase KRas-driven NSCLC mouse models [12], suggesting that the attenuation of the H1.2-Nrf2 axis could be a potential therapeutic strategy against lung cancer progression. The gene discussed is H1-2; the disease is cancer.